Ardent Health Partners, Inc. (ARDT) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Ardent Health Partners, Inc. stock $21.20, price $17.30, upside +22.5%, quality 55 out of 100. Rating: undervalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.
How to read this chart
28‑month range $7.83 – $20.19 · fair‑value band $13.60 – $26.50 · the $17.30 price screens below the $21.20 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.
Follow Ardent Health Partners in your weekly email
Every Wednesday you see whether Ardent Health Partners is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Ardent Health, Inc. owns and operates a network of hospitals and clinics that provides healthcare services in the United States.
Show moreShow less
The company offers general and specialty services, including internal medicine, general surgery, cardiology, oncology, orthopedics, women's services, neurology, urology, and emergency services within inpatient and ambulatory care settings.
It also operates a network of ambulatory facilities and telehealth services, including primary care and specialty care clinics, ambulatory surgery centers, urgent care centers, free-standing emergency departments, and diagnostic imaging centers.
The company operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. Ardent Health, Inc. was formerly known as Ardent Health Partners, Inc. and changed its name to Ardent Health, Inc. in June 2025. The company was founded in 2001 and is based in Brentwood, Tennessee.
Ardent Health, Inc. is a subsidiary of EGI-AM Investments, L.L.C.
Stock analysis
Ardent Health Partners, Inc. (ARDT) currently trades at $17.30, while our model-based Fair Value estimate is $21.20, implying the stock looks roughly 18% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $23.23 per share, and 14 of the 24 models we run sit above the $17.30 price.
Bear case: the Asset-Based group reads lowest at $3.41, and 10 of the 24 models stay below the price. Data coverage for this calculation is medium.
Scenario range: $13.60 (bear) to $26.50 (bull), the price of $17.30 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 55/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Ardent Health Partners, Inc. reported revenue of $6.3B in FY2025 versus $4.9B in FY2021, a compound +6.7%/yr. Reported net income was $136M in FY2025, compounding −3.1%/yr from FY2021.
Key figures
Market cap $2.5B Mid · P/E ratio 16.8 · P/S ratio 0.38 · EPS (TTM) $1.03 · Net margin 2.3% · Return on equity 13.5% · Return on assets (EBIT) 5.8% (4-year average) · Operating margin 5.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 40 out of 100 (medium confidence).
What moves the price
The share trades at its 52-week high and 121% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at 23%, ARDT screens cheaper than that median.
Fair Value models
Bear$13.60Fair Value $21.20Bull$26.50
Price $17.30 · Upside +22.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($0.8804 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, 2 officers or directors bought shares worth $186,400, most recently on Jun 5, 2026. Buying cluster
BuyAlfred LumsdaineChief Financial Officer10,000 shares at $8.81$88,100Jun 5, 2026
BuyRobert DeMichieiDirector11,260 shares at $8.73$98,300Jun 5, 2026
Plus 4 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.66/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+6.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.2%
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.0%
’15
’16
’17
’18
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−2.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year−2.3%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−2.3% vs 24.9%, slowing
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.9% → 5%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−3.5%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+3.3%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about −5.8% a year for the price and +0.9% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (90 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Positive
Recent news coverage is more positive than average.
Compare Ardent Health Partners, Inc. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 233 stocks
Beats the industry median on 7/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score55 · Below median
Fair Value upside+22.5% · Above median
Profitability
Return on equity (12 months)13.5% · Above median
Return on assets4.4% · Below median
Net margin (12 months)3.9% · Below median
Operating margin (12 months)5.9% · Below median
Growth and dividend
Revenue growth (quarter YoY)3.1% · Below median
Balance sheet
Debt / equity0.64× · Highest 25%
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
P/E (12 months)16.8× · Cheaper than median
P/B1.47× · Cheaper than median
P/S (12 months)0.65× · Cheapest 25%
Price / free cash flow (fiscal year)16.2× · Cheaper than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Ardent Health Partners, Inc. Fair Value". https://www.fairvalue-calculator.com/stock/ARDT
Frequently asked questions
Is Ardent Health Partners, Inc. (ARDT) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of $21.20 versus a price of $17.30, about +23% upside (undervalued).
What is the fair value of ARDT?
Our model-based fair value for Ardent Health Partners, Inc. is $21.20 (as of Nov 7, 2026), built from audited fundamentals. The current price: $17.30.
What is the quality score of ARDT?
Ardent Health Partners, Inc. has a Quality Score of 55/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Ardent Health Partners, Inc. (ARDT)?
Our model-based price target is the fair value of $21.20 (as of Nov 7, 2026) from 24 valuation models. Cautious scenario $13.60, optimistic scenario $26.50. It is a calculation from audited fundamentals, not an analyst target.
What is the Ardent Health Partners, Inc. stock forecast for 2026?
Our models put fair value at $21.20, about +23% upside versus a price of $17.30 (undervalued). Cautious scenario $13.60, optimistic scenario $26.50. The calculation is refreshed regularly with new filings.
What is the revenue of Ardent Health Partners, Inc. (ARDT)?
Ardent Health Partners, Inc. reported trailing-twelve-month revenue of about $6.5B (latest available figure, as of Nov 7, 2026).
What growth is priced into Ardent Health Partners, Inc. (ARDT)?
For today's price to be fair in a discounted-cash-flow model, Ardent Health Partners, Inc. would have to grow free cash flow by -3.5 % per year for five years (discount rate 8.7 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 7 years revenue grew +6.2 % per year. As of Nov 7, 2026.
What discount rate (WACC) does the fair value of ARDT use?
Our models discount Ardent Health Partners, Inc. at 8.7 %: a base by market capitalisation (mid), damped by beta 0.58, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Ardent Health Partners, Inc. that is -3.5 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (8.7 %) and the same formula as our fair value.
How much growth has Ardent Health Partners, Inc. (ARDT) delivered so far?
Over the past 7 years revenue at Ardent Health Partners, Inc. grew +6.2 % a year. The price currently implies free-cash-flow growth of -3.5 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Ardent Health Partners, Inc. (ARDT) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Ardent Health Partners, Inc. (-3.5 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Ardent Health Partners, Inc. (ARDT)?
The free-cash-flow yield on the price is 10.45 %: that much free cash flow Ardent Health Partners, Inc. produces per unit of market value. When it exceeds the discount rate of our models (8.7 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Ardent Health Partners, Inc. (ARDT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Ardent Health Partners, Inc. it is $21.20 per share (as of Nov 7, 2026), against a price of $17.30. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Ardent Health Partners, Inc. stock overvalued or undervalued in 2026?
As of Nov 7, 2026, ARDT trades below its calculated fair value: price $17.30, fair value $21.20, a gap of about +23% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ARDT?
No. The price is what the market pays today ($17.30); the fair value is what the company's own numbers justify ($21.20). For Ardent Health Partners, Inc. the two are $3.90 per share apart. That gap is exactly why we show both numbers side by side.
How much is Ardent Health Partners, Inc. worth?
The market values Ardent Health Partners, Inc. at about $2.5B (market capitalisation, as of Nov 7, 2026). Per share that is $17.30; our models calculate a fair value of $21.20 per share.
What do the bullish and bearish scenarios say about ARDT?
Our models span a range for Ardent Health Partners, Inc.: cautious scenario $13.60, base $21.20, optimistic $26.50 per share (as of Nov 7, 2026, price $17.30). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ARDT?
Ardent Health Partners, Inc. trades at a price-to-earnings ratio of 16.8 (as of Nov 7, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $21.20 is built from several models across several years. Other multiples: P/B 1.5, P/S 0.6, EV/EBITDA 9.6.
How solid is the balance sheet of Ardent Health Partners, Inc. (ARDT)?
Balance-sheet figures for Ardent Health Partners, Inc. (as of Nov 7, 2026): return on equity 13.5%, debt of 0.64 per unit of equity. They feed the Quality Score of 55/100, which measures business quality independently of the share price.
How far is ARDT from its 52-week high?
Ardent Health Partners, Inc. trades at $17.30, at its 52-week high of $17.30 and 121% above the low of $7.83 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $21.20 is for.
Which stocks are comparable to Ardent Health Partners, Inc.?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Ardent Health Partners, Inc. stock attractive at the current price?
The data as of Nov 7, 2026: price $17.30, calculated fair value $21.20 (+23%), Quality Score 55/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ARDT calculated?
We run Ardent Health Partners, Inc. through 24 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $21.20 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Ardent Health Partners, Inc. currently trades 18% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Ardent Health Partners, Inc. (ARDT)?
The closing price on Nov 6, 2026 was $17.30. Our model-based fair value is $21.20, about +23% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Ardent Health Partners, Inc. right now?
Solid quality (55/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range ($13.60 to $26.50) leaves room in how you read the outcome.
Key figures of Ardent Health Partners, Inc.
How large is the market capitalisation of Ardent Health Partners, Inc. (ARDT)?
The market capitalisation of Ardent Health Partners, Inc. is $2.5B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Ardent Health Partners, Inc. (ARDT)?
The price-to-sales ratio of Ardent Health Partners, Inc. is 0.38 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Ardent Health Partners, Inc. (ARDT)?
Earnings per share at Ardent Health Partners, Inc. are $1.03 (price ÷ EPS = P/E 16.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Ardent Health Partners, Inc. (ARDT)?
The net margin of Ardent Health Partners, Inc. is 2.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Ardent Health Partners, Inc. (ARDT)?
The return on equity (ROE) of Ardent Health Partners, Inc. is 13.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Ardent Health Partners, Inc. (ARDT)?
On an EBIT basis the return on assets of Ardent Health Partners, Inc. is 5.8% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Ardent Health Partners, Inc. (ARDT)?
The operating margin of Ardent Health Partners, Inc. is 5.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Ardent Health Partners, Inc. (ARDT)?
Revenue at Ardent Health Partners, Inc. is growing +3.1% versus a year earlier (3y avg +7.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Ardent Health Partners, Inc. (ARDT)?
Earnings per share at Ardent Health Partners, Inc. are growing −77.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Ardent Health Partners, Inc. (ARDT) carry?
The net debt of Ardent Health Partners, Inc. is $1.6B (fiscal year 2025, ≈ 6.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Ardent Health Partners, Inc. in the live analysis
One click puts Ardent Health Partners, Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 7, 2026